MusclePharm: ‘We made an intentional decision to stay away from DMAA’

By Elaine Watson

- Last updated on GMT

Related tags: Amino acid, Nutrition

MusclePharm 'made an intentional decision to stay away from DMAA' when it formulated Assault, claim bosses
MusclePharm 'made an intentional decision to stay away from DMAA' when it formulated Assault, claim bosses
MusclePharm “made an intentional decision to stay away from DMAA” when it formulated its pre-workout supplement Assault, say bosses at the Colorado-based sports nutrition expert.

Assault is likely to gain a wider market share following the FDA’s crackdown​ on supplements containing DMAA (1,3-Dimethylamylamine), predicts MusclePharm, the first - no doubt of many - firms to see an opportunity in the events of the last few days.

Chief science director Dr Roscoe Moore said: “MusclePharm made an intentional decision to stay away from DMAA when it formulated Assault, for the same reasons the FDA has now banned the ingredient. 

"We believe this differentiates MusclePharm from its competitors and ensures our products are backed by real science."

Proven to naturally increase performance in athletes

Assault, claims MusclePharm, has become the No. 1-selling pre-workout supplement on Bodybuilding.com and is “the only pre-workout product on the market certified by both NSF International and Informed Choice as free of banned substances​”.

It added: “Assaultcontains large amounts of Branch-Chain Amino Acids (BCAAs) and Beta Alanine and Creatine, which have been proven to naturally increase performance in athletes​.”

A clinical trial published in Nutrition and Metabolism​ earlier this year showed that ingesting Assault 20 minutes before exercise can improve agility, quickness and lower-body muscular strength in both strength and/or endurance-trained young men, added the firm. Click here​ for details.

MusclePharm raises 2012 forecasts as Q1, 2012 sales surge

MusclePharm posted an almost four-fold rise in net sales to $19m in the first quarter of 2012 - up from $4m in Q1, 2011 - while income from operations rose to around $1m versus a loss of $1m in Q1, 2011. 

Chief executive Brad Pyatt said: “Due to the strong demand we are seeing for our products, combined with the expected near-term launch of 15 new products, we have adjusted our projections for 2012 net sales to $75m from $40m."

Chief operating officer John Bluher said MusclePharm was also aiming to go public: "We are not only focused on growing our business but also moving as effectively as possible to qualify for listing on a national stock exchange.” 

MusclePharm’s products focus on muscle building, weight loss and maintaining general fitness.

Related news

Show more

Related products

show more

Pronativ® | An Essential Nutrient-Rich Protein

Pronativ® | An Essential Nutrient-Rich Protein

Lactalis Ingredients | 06-Jul-2020 | Technical / White Paper

Differentiate your protein product with a nutrient-rich protein ingredient.
Pronativ® native whey protein, produced by Lactalis Ingredients, is...

Pycnogenol® Improves Fitness and Muscle Recovery

Pycnogenol® Improves Fitness and Muscle Recovery

Horphag Research | 29-Jun-2020 | Clinical Study

Published studies show daily supplementation of Pycnogenol® is effective in boosting muscle performance, increasing endurance and reducing cramping and...

Related suppliers

1 comment

Good on MusclePharm

Posted by Trey,

I think MusclePharm did a good thing not using DMAA, safe or not I do not belive it is a legal supplement as per WADA standards. There are many great pre wortkouts that use safe and effective ingredients

Report abuse

Follow us

Products

View more

Webinars